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S T R U C T U R A L  B I O L O G Y
Termini restraining of small membrane 
proteins enables structure determination at 
near-atomic resolution
Shixuan Liu, Shuang Li, Yihu Yang, Weikai Li*
Small membrane proteins are difficult targets for structural characterization. Here, we stabilize their folding by 
restraining their amino and carboxyl termini with associable protein entities, exemplified by the two halves of a 
superfolder GFP. The termini-restrained proteins are functional and show improved stability during overexpression 
and purification. The reassembled GFP provides a versatile scaffold for membrane protein crystallization, enables 
diffraction to atomic resolution, and facilitates crystal identification, phase determination, and density modification. 
This strategy gives rise to 14 new structures of five vertebrate proteins from distinct functional families, bringing 
a substantial expansion to the structural database of small membrane proteins. Moreover, a high-resolution structure 
of bacterial DsbB reveals that this thiol oxidoreductase is activated through a catalytic triad, similar to cysteine 
proteases. Overall, termini restraining proves exceptionally effective for stabilization and structure determination 
of small membrane proteins.
INTRODUCTION
Integral membrane proteins constitute approximately 30% of pro-
teomes in prokaryotes and eukaryotes, and they represent more 
than half of the drug targets. Elucidating their molecular functions 
and facilitating the development of new drugs requires knowledge 
of their three-dimensional structures. Structural studies generally 
start from protein overexpression in cells, followed by protein puri-
fication from the native membranes with selected detergents. 
These operations frequently disrupt the function and folding of 
membrane proteins, resulting in their denaturation and aggrega-
tion (Fig. 1). To overcome this difficulty, structural biologists often 
perform large screens of homologous proteins to identify a few that 
show sufficient stability during overexpression and purification (1). 
Most membrane proteins, however, need to have their instability 
and flexibility reduced before they can be structurally characterized. 
One approach to enhance protein thermostability is systematic mu-
tagenesis of the entire protein to identify multiple synergistically 
stabilizing mutations, a trial-and-error method that requires te-
dious effort (2–4). Another time-consuming and costly approach is 
the search of suitable antibodies that can stabilize a flexible region 
of membrane proteins and provide a scaffold for cocrystallization (5) 
or cryo–electron microscopy (cryo-EM) analyses (6). Structure 
determination of heterotrimeric GTP-binding protein (G protein)–
coupled receptors (GPCRs) can be accomplished by replacing an 
intracellular loop in GPCRs with a highly crystallizable soluble protein 
(7, 8). However, there are limited reports of applying this engineering 
method to obtain structures of membrane proteins from other families, 
because it is unknown which flexible loops should be replaced, and 
the replacement is restricted by the size of the soluble protein. 
Moreover, lessons learned from GPCRs are that their G protein 
coupling function is compromised by the replacement of the intra-
cellular loop (7), by an antibody bound to this functionally essential 
loop (9), and even by heterologous overexpression in insect cells 
(10). Together, maintaining the native structure and function of 
membrane proteins in vitro remains the biggest hurdle to overcome 
for structural biologists (11).
Structure determination of small membrane proteins poses addi-
tional challenges. More than 60% of membrane proteins have fewer 
than the seven transmembrane helices (TMs) that GPCRs have (12). 
These small proteins are difficult targets for crystallography. With 
their membrane portion buried in the detergent micelles, these pro-
teins are often left with either small exposed regions that can barely 
provide crystal contacts or large flexible loops that may destabilize 
crystal contacts (Fig. 1). Because many of these proteins are not sub-
units of a large and stable assembly, their small size generally places 
them beyond the reach of cryo-EM techniques, which are currently 
striving toward a minimum size of ~100 kDa for membrane proteins. 
As a result, small membrane proteins are much underexplored by 
structural biology. Taking the example of four-TM proteins, struc-
tures have been reported so far for only six individual proteins—
CD81 (13), CD9 (14), Cldn4 (15), Cldn9 (16), DHHC20 (17), and 
SCD1 (18)—from hundreds of these in the human genome (19). To 
meet this critical challenge, here, we develop a termini-restraining 
approach to facilitate the entire structure determination process of 
small membrane proteins. This new approach gives rise to 14 struc-
tures of five proteins from humans and other vertebrates, whose 
structures were unknown from traditional approaches, and a high- 
resolution structure of bacterial disulfide bond formation protein B 
(DsbB) that reveals its catalytic chemistry, thereby bringing a sub-
stantial expansion to the current structural database of small mem-
brane proteins.
RESULTS
Design principles of termini restraining
Our strategy is to stabilize small membrane proteins by restraining 
their two termini with a coupler formed of two associable protein 
entities (Fig. 1). As a proof of concept, we fused the N and C termini 
of the membrane proteins to the N- and C-terminal halves of a 
superfolder green fluorescent protein (sfGFP), respectively; split 
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sfGFP has been optimized for efficient self-association in previous 
works (20, 21). Tethering this soluble coupler protein to the two 
flexible termini of the membrane proteins provides a mild restraint, 
hampering the drastic TM motions that lead to unfolding and thus 
favoring their folded state during protein overexpression and puri-
fication. The flexible portions of the two termini loosely connect the 
coupler to the first and last TMs of membrane proteins, permitting 
moderate conformational changes that are usually sufficient for 
the normal protein function. This approach requires that the two 
termini of the target proteins are located on the same side of the 
membrane. Given that most membrane proteins are predicted to 
have even numbers of TMs and to have both termini in the cytosol 
(22, 23), this engineering strategy can be applied to numerous 
membrane proteins with such folding topology.
Selection of small membrane proteins
To test the generality of our approach, we selected seven model 
proteins from humans or other vertebrates (Table 1) that were con-
sidered difficult structural targets. These small membrane proteins 
(10 to 40 kDa) contain even numbers of TMs (2, 4, 6), but their 
three- dimensional structures were unknown. These proteins 
represent distinct functional families, including membrane enzymes, 
adhesion molecules, and transporters. Vitamin K epoxide reductase 
(VKOR) and VKOR-like (VKORL) are thiol oxidoreductases. Signal 
peptidase complex subunit 1 (SPCS1) is a serine protease subunit 
required for the processing of flaviviral proteins (24). CD53 is a mem-
ber of the tetraspanins (25). Claudin 4 (Cldn4) forms the backbone 
of tight junction (15). Jagunal homolog 1 (JAGN1) is involved in 
vesicle- mediated transport (26). Mitoferrin-1 (Mfrn1) belongs to the 
SLC25 carrier family that transports solutes across the mitochon-
dria inner membrane (27). We have also included DsbB, a bacterial 
oxidoreductase that has been previously cocrystallized with its partner 
protein (DsbA) or in the presence of an antibody (28, 29), but these 
tremendous measures produced structures of only moderate res-
olution (3.4 to 3.7 Ǻ) that lack protein side-chain information (30). 
Thus, DsbB serves as a benchmark that allows us to compare the 
result of structure determination by traditional methods and by our 
termini- restraining approach.
Retained protein functions after termini restraining
Our first priority was to confirm that termini restraining does not 
compromise protein functions. The restrained VKOR and VKORL 
retain their cellular reductase activity and became slightly more 
sensitive to the inhibition by warfarin, an anticoagulant targeting 
these enzymes (Fig. 2A). A historically challenging example of protein 
instability, human VKOR rapidly loses enzymatic activity during 
purification; this prevented the biochemical identification of this 
protein before the genomic era (31). With the two termini restrained, 
purified human VKOR shows a specific activity 20 times higher than 
the unrestrained protein does (Fig. 2B), suggesting that the restraining 
markedly increases protein stability. Similarly, the specific activity 
of the restrained VKORL is five times higher than that of the wild-
type VKORL (Fig. 2B). The restrained DsbB, like the wild-type DsbB, 
can promote disulfide bond formation in Escherichia coli; both con-
structs complement the motility defect of a ∆dsbB strain (32) and 
inactivate a disulfide-sensitive -galactosidase fusion protein (Fig. 2C) 
(33). Cldn4, another protein that we could assay for function, re-
tains interactions of forming high-order complexes at the cell junction 
after the sfGFP restraining (Fig. 2D). In particular, the restrained 
Mfrn1, which needs to transport iron via large rocking motions 
(34), exhibits high activity in liposomes as the unrestrained Mfrn1 
does (Fig. 2E). Together, these examples indicate that termini re-
straining maintains the transport activity, enzymatic activity, and 
molecular interaction of these representative membrane proteins, 
even when large conformational changes are required for their 
functions.
Protein stability during overexpression and purification
Because overexpression often causes misfolding or aggregation of 
membrane proteins (10, 35), we compared the sfGFP-restrained 
proteins with those tagged with a C-terminal GFP (C-GFP). Fluo-
rescence imaging showed that termini restraining does not change 
the subcellular localization of these proteins (Fig. 2F and fig. S1). 

















































Fig. 1. Termini restraining of small membrane proteins facilitates their entire 
structure determination process. (Left) Difficulties with traditional structural bi-
ology approaches (blue box). (I) Overexpression of membrane proteins increases 
their tendency to unfold and aggregate in cells. The unfolding involves large rela-
tive motions between TMs (dashed arrow). (II) Protein purification in detergents is 
often disruptive to the native folded state of membrane proteins. (III) Small mem-
brane proteins in detergent micelles often contain either small exposed regions or 
large flexible loops, both of which increase the difficulty of making crystal contact. 
These proteins are also too small for structural determination by cryo-EM. (Right) 
Termini-restraining strategy (orange box). (I′) Two associable protein entities (cou-
pler; green) are fused to the flexible N and C termini of a membrane protein (blue), 
providing a loose restraint to stabilize its folded state during protein overexpression 
in cells (I′) and protein purification in detergents (II′). (III′) Introducing the coupler 
protein also provides a large surface for crystal packing and facilitates structure 
determination.
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Table 1. Summary of small membrane proteins, enhancement of protein stability after termini restraining, and improvement of structural resolution 
after termini shortening. ER, endoplasmic reticulum; MW, molecular weight; Tm, melting temperature; TR, termini restraining; N/A, not analyzed or not 
available; War, warfarin; n.p., autobuilding not performed because of poor data quality; PDB, Protein Data Bank. 
Protein SPCS1 VKOR* VKORL* DsbB JAGN1 CD53 (43) Cldn4 Mfrn1

































TM no. 2 4 4 4 4 4 4 6
MW (kDa) 11.6 18.2 19.6 20.1 21.1 24.3 22.1 36.7
Length (amino 
acids) 101 163 175 176 183 219 209 338
Protein stability
 Folded protein† + ++ +++ +/− +++ − +/− ++
 Tm before TR (°C) 64.6 49.2 53.3 49.5 57.8 79.7 85.2 58.9
 Tm after TR (°C) 64.4 52.1 62.1 >90 66.3 80.2 73.0 60.2
Activity or 
function N/A Improved Improved Maintained N/A N/A Maintained Maintained
Crystallization
 Initial (amino 
acids) 1–80 Full length (War) Full length 6–170
‡ Full length Full length 1–184 N/A
  Resolution (Å) ~5 5.7 4.3 3.7 2.25 2.9 N/A N/A
  Space group C222 P222 P43212 P2 C2 P2
  Cell dimensions





   , ,  (°) 90, 90, 90 90, 90, 90 90, 90, 90 90, 96.5, 90 90, 103.8, 90 90, 100.2, 90
  Solvent content 69.2% 59.3% 65.5% 62.3% 67.0% 45.6%












  Auto 
building§ n.p. n.p. 57.9% n.p. 93.4% 96.4%
 Shortened 
(amino acids) 1–75 3–155 (War) 6–175 6–167 N/A N/A N/A N/A
  Resolution (Å) 2.45 2.2 2.4 2.9
  Space group C2 P21212 C2 P3221
  Cell dimensions
   a, b, c (Å) 105.0, 55.3, 92.7 47.4, 70.9, 153.1 153.6, 49.1, 84.3 53.4, 53.4, 280.7
   , ,  (°) 90, 110.9, 90 90, 90, 90 90, 112.7, 90 90, 90, 120
  Solvent content 65.2% 57.8% 60.8% 52.2%








  Auto 
building§ 90.5% 84.3% 97.8% 83.1%
Rwork/Rfree (%) 20.4/23.2 20.1/22.3 20.5/23.7 26.0/28.6 19.5/22.7 22.3/26.5 N/A N/A
continue to next page
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proteins with even numbers of TMs fold properly in their predicted 
topologies (36). Some of the C-GFP–tagged proteins, such as VKORL, 
appear to accumulate in the endoplasmic reticulum (ER) and/or 
vacuoles, whereas the sfGFP-restrained proteins are distributed 
evenly at the ER membrane boundary. To understand this difference, 
we compared the whole-cell extraction of the restrained and unre-
strained proteins in the presence of SDS, SDS/urea, and n-dodecyl-
-D-maltoside (DDM) detergents, the latter of which preferably 
solubilizes correctly folded membrane proteins (10). For C-GFP–tagged 
VKOR, VKORL, JAGN1, SPCS1, and Mfrn1, the amount of DDM- 
extractable protein was much less than that extractable by SDS 
and/or SDS/urea, indicating that a large portion of these recombinant 
proteins are expressed in aggregated or insoluble form (Fig. 2G). In 
contrast, termini restraining substantially increases the DDM- extractable 
fraction of these ER and mitochondrial proteins, indicating that the 
restraining can prevent protein aggregation during overexpression. 
The relative level of DDM- extractable protein, however, is similar for 
the restrained and unrestrained DsbB from E. coli cytoplasmic mem-
brane. For the human proteins located on the cytoplasmic membrane, 
we found that the DDM-extractable fraction remains nearly unchanged 
for restrained Cldn4 and becomes less for restrained CD53, probably 
because these cell surface proteins are intrinsically stable and therefore 
their stability is not improved by termini restraining. Overall, although 
we did not observe improvement for every protein, the restraining 
affords a readily testable approach to increase the effective pro-
duction of membrane proteins, presumably through stabilizing their 
folded state in cells.
The ability of proteins to maintain their folded state usually 
correlates with their thermostability (37). Therefore, we measured 
the melting temperature (Tm) of proteins purified in detergent 
solution by using fluorescence-detected size exclusion chromatog-
raphy (FSEC), a well-established assay for membrane protein stability 
(38). To allow precise comparison, we tagged the sfGFP-restrained 
and unrestrained constructs with a C-terminal mCherry for FSEC 
detection. This design avoids the Tm comparison between split and 
integral GFPs; instead, the sfGFP serves only as the coupler, and the 
Tm is measured through the change of mCherry signal. The re-
straining raised the Tm by 8.8°C for VKORL and 8.5°C for JAGN1 
(Fig. 2H). The Tm change of DsbB after restraining is even more 
substantial, from 50°C to more than 90°C. The comparison of 
VKOR proteins required further stabilization with bound warfarin, 
under which condition the restraining increased the Tm by 2.9°C. 
The restraining slightly changes the Tm of SPCS1, CD53, and 
Mfrn1, and lowers that of Cldn4, probably because the unstrained 
Cldn4 has an inherently high Tm (85°C). This restraining approach 
thus appears to be more effective at improving the detergent stabil-
ity of proteins with relatively low Tm.
Crystallization and structure determination
Seven restrained membrane proteins—VKOR, VKORL, CD53, SPCS1, 
Cldn4, JAGN1, and DsbB—could be readily crystallized in lipidic- 
cubic phase (LCP) (Table 1). We optimized all the crystals except 
Cldn4, whose structure was reported during our study (15). The 
effort of optimization was immediately justified, because the sfGFP 
coupler can be detected under fluorescence microscope. Even tiny 
protein crystals can be distinguished from other particles made of 
salt, detergent, or lipids (Fig. 3A). Traditionally, it requires months 
of effort to optimize the initial hits and allow crystals to grow large 
enough to confirm the presence of the target protein by crystal dif-
fraction pattern or by silver staining of dissolved crystals. The sfGFP 
coupler bypasses this technical bottleneck.
The sfGFP coupler affords a highly versatile scaffold for the 
crystallization of small membrane proteins, which have different 
sizes, shapes, and surface properties (Fig. 3B and fig. S2A). Each of 
the sfGFP-restrained proteins crystallized in a different space group 
or with different unit cell dimensions (Table 1, table S1, Fig. 3C, and 
fig. S2B). Even for the same protein, VKOR or VKORL, alternative 
reactive states or different bound ligands generated five and three 
different crystal forms, respectively (table S2 and fig. S2C). Despite 
these differences, the crystal lattices are always packed into two al-
ternative layers, one made by sfGFP molecules and another by the 
small membrane proteins (Fig. 3C and fig. S2, B and C). Crystal 
contacts can also be formed between the TM regions of the mem-
brane protein molecules, likely induced by the LCP crystallization 
condition. To accommodate the different membrane proteins, sfGFP 
molecules form various lattice packing interactions using nearly 
every part of its large polar surface (Fig. 3D). None of the 12 crystal 
forms exhibits the same packing pattern in the layer of sfGFP mol-
ecules (fig. S2, B and C). This remarkable adaptability shows that 
termini restraining by sfGFP is broadly applicable to crystallizing 
small membrane proteins.
The quality of crystal diffraction is markedly improved by shorten-
ing the flexible termini regions of membrane proteins tethered to 
sfGFP. This shortening induced alternative crystal packing. For in-
stance, crystals of the restrained full-length VKORL only diffracted to 
4.3 Å (Fig. 4A). Shortening the N terminus of VKORL by a mere five 
amino acids changed the space group from P43212 to C2 (Table 1) 
with completely different crystal packing interactions (Fig. 4B), prob-
ably by restricting the relative motion between sfGFP and VKORL 
molecules. As a result, the remaining part of the VKORL N terminus 
becomes ordered in the C2 crystal form, and the orientation of 
VKORL with respect to sfGFP becomes different (Fig. 4C). The 
solvent content decreases by 5%, and the crystal diffraction im-
proves to 2.4 Å (Fig. 4A). Similar termini optimizations changed the 
crystal packing of VKOR, DsbB, and SPCS1 (Table 1) and markedly 








6WVF 6WVD 6WVG N/A N/A
*Biological interpretations of the VKOR and VKORL structures are being reported in an accompanying manuscript (42).   †Changes in the fraction of folded 
membrane proteins after TR are roughly estimated (+ or − signs) from the whole-cell extraction of overexpressed proteins with SDS, SDS/urea, and 
DDM.   ‡This construct was used according to Inaba et al. (28).   §Autobuilding was performed with BUCCANEER using the density modification maps 
generated from PARROT (see Materials and Methods).
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Fig. 2. Termini restraining maintains the functions of small membrane proteins and enhances their stability during overexpression and purification. (A) Cellular 
activities of termini-restrained (TR) and unrestrained constructs of VKOR and VKORL in response to warfarin inhibition. (B) Activities of purified VKOR and VKORL con-
structs at the same protein concentration. (C) DsbB-catalyzed disulfide bond formation. Left: Transformations restore the motility (measured by colony size) of ∆dsbB 
E. coli. EV, empty vector. Right: Disulfide-mediated inactivation (white colonies) of MalF-fused -galactosidase. (D) Cldn4-mediated cell junction. Fluorescence images are 
of live human embryonic kidney (HEK) 293 cells transfected with Cldn4 constructs. (E) Fe2+ uptake activity of purified Mfrn1 in liposomes (50). Cal, calcimycin. See Materials 
and Methods for explanation of assays in (A) to (E). (F) Fluorescence images of live Pichia cells overexpressing ER membrane proteins with C-GFP tag or sfGFP restraining. 
The merged images combine GFP fluorescence with ER marker. Red arrows indicate potential protein accumulation in the ER and/or vacuoles. DIC, differential interference 
contrast. (G) Comparison of extractable folded membrane protein fraction with or without the termini restraining. The immunoblots are shown for target proteins extracted 
from whole cells with SDS, SDS/urea, or DDM. (H) FSEC-based thermostability assay of purified proteins showing change of Tm (Tm) with termini restraining. The 
unrestrained (U) and sfGFP-restrained constructs both carry a C-terminal mCherry tag for fluorescence detection.
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improved their crystal diffractions to near-atomic resolution 
(up to 2.0 Ǻ).
The crystallographic phase problem was solved using the structural 
model and diffraction data of the sfGFP coupler. Molecular replace-
ment (MR) with the sfGFP model [Protein Data Bank (PDB) code 
2B3P] readily generated solutions for all datasets, because the mem-
brane proteins are small and sfGFP constitutes a relatively large portion 
of the diffraction mass. For the high-resolution datasets, after rigid 
body refinement of the MR model and solvent flattening with auto-
matically generated mask, the electron density maps (figs. S3 and S4), 
which are unbiased at the membrane protein region, allowed auto-
matic model building for a major part (often above 90%) of the target 
proteins (Table 1). Even at low resolution, the initial MR phases could 
be markedly improved by cross-crystal averaging (39) with the dif-
fraction data of sfGFP alone (Fig. 4D). For instance, averaging the 
sfGFP data with the 4.3-Å VKORL data [twofold noncrystallographic 
symmetry (NCS)] generates a well-featured electron density map 
(Fig. 4E) that allowed correct building of nearly all TMs (Fig. 4F). The 
same cross-crystal averaging approach is also useful for data at higher 
resolution and without NCS, such as the 2.9-Å data of DsbB (fig. S5). 
Overall, model phasing with the sfGFP coupler avoids experimental 
phasing, a tedious and sometimes unsuccessful process.
The termini-restraining approach yields the first structures of five 
small membrane proteins from humans and other vertebrates (Fig. 5A). 
The structures of VKOR and VKORL, unlike their bacterial homolog 
structures (fig. S6) (40, 41), elucidate almost their entire catalytic cycle 
and their mechanism of inhibition by warfarin and other antagonists, 
which are oral anticoagulants commonly used to treat and prevent 
thromboembolic diseases such as stroke and heart attack (42). The 
crystal structure of CD53 is the first structure ever captured of the 
partner-interacting state for the entire tetraspanin family (43), which 
mediates molecular interactions for myriad cellular processes (25). 
SPCS1 is a major therapeutic target of Zika virus (24), and its struc-
ture suggests a regulatory role for this signal peptidase subunit during 
the maturation process of Zika and other flaviviruses. Last, the 
JAGN1 structure reveals a unique structural fold that may allow 
specific interaction with proteins involved in vesicle-mediated trans-
port. Thorough analyses of these new structures are being reported 
elsewhere (42, 43); here, we focus on the benchmark example, DsbB, 
a disulfide bond formation enzyme.
Maintained DsbB structure after termini restraining
The overall structure of termini-restrained DsbB (Fig. 5A) closely 
matches previously determined structures of DsbB, indicating that 
the restraining does not disrupt the protein conformation. The 
transmembrane region of restrained DsbB has a root mean square 
deviation (RMSD) of 1.1 Å to that of 2ZUQ (Fig. 5B) (29). The short 
-hairpin that folds on top of TM4 is also maintained. The confor-
mation of a long loop connecting TM3 and TM4 is similar to the 
nuclear magnetic resonance (NMR) structure of a Cys44Ser/Cys104Ser 
mutant (44) because of formation of the same interloop disulfide, 
Cys130-Cys41 (Fig. 5C). This interloop disulfide is induced by a 
Cys104Ser mutation, which also allows a charge-transfer complex to 
form between Cys44 and the quinone cofactor of DsbB in our struc-
ture (fig. S7).
DsbB activation by a catalytic triad
The high-resolution structure reveals that thiolate activation in 
E. coli DsbB uses a catalytic triad that is reminiscent of the classical 
mechanisms used by cysteine or serine proteases (Fig. 5D). The 
electron density maps clearly show the protein side chains and the 
quinone ring at the active site (fig. S5C). The quinone ring is stacked 
between Arg48 at the bottom and Cys44 and Met142 on the top. Cys44, 
His91, and Glu47 form the catalytic triad, whose spatial arrangement 
is essentially the same as that observed in the cysteine proteases 
(Fig. 5D) (45, 46). Thus, a similar mechanism may be used by the 
thiol oxidoreductase DsbB to activate Cys44 (Fig. 5E). This process 
starts from the deprotonation of His91, probably with assistance 
from Glu47. Next, His91 abstracts the proton from the sulfhydryl 
group of Cys44, generating a nucleophile to attack the quinone. The 
negative charge of Cys44 thiolate is not stabilized by Arg48 (29) be-
cause it is on the other side of the quinone ring. Instead, Arg48 may 
































Fig. 3. The sfGFP coupler enables crystallization of small membrane proteins. 
VKORL and SPCS1 are shown as examples here; other proteins are shown in fig. S2. 
(A) Identification of initial crystallization hits (left) of sfGFP-restrained VKORL 
through fluorescence imaging. The optimized crystals (right) are shown for comparison. 
(B) Electrostatic surfaces of VKORL and SPCS1 showing their different shapes and 
surface charges (blue, positive charge; red, negative charge). (C) sfGFP serves as a 
crystal packing scaffold that is highly adaptable to accommodate various small 
membrane proteins. Each crystal is packed with alternative layers (dashed lines) of 
sfGFP (green) and small membrane protein (SMP) molecules. The TMs (numbered) 
are shown in blue, and extramembrane regions are shown in red. Different mem-
brane protein molecules in the crystals are indicated (A and B). (D) Zoom-in view of 
versatile crystal packing interactions formed among sfGFP molecules. The large 
polar surface of sfGFP can accommodate a multitude of crystal contacts (purple 
surface). The  strands in sfGFP are numbered to illustrate location of the contacts.
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stabilize the entire charge-transfer complex and also facilitate its 
formation through inducing polarization of the quinone ring. Con-
sistent with this mechanism, Arg48 and His91 are two of the most 
conserved residues in DsbB homologs (47). Moreover, mutations of 
Arg48, His91, and Glu47 show accumulation of DsbB-DsbA complex 
and/or reduced quinone binding (47, 48), both of which may result 
from impaired Cys44 reactivity. The quinone reduction activity of 
His91Ala and Glu47Ala mutants is also drastically reduced (fig. S8). 
Together, these new insights gained from our termini-restraining 
approach offer a much clearer picture of the redox chemistry of 
E. coli DsbB.
DISCUSSION
With termini restraining, structural determination of small mem-
brane proteins at near- atomic resolution becomes relatively routine. We 
have obtained a total of 15 crystal structures of six different proteins 
(42, 43), three of which are of human origin and two from other 
vertebrates (Table 1 and Fig. 5A). Obtaining the structure of an in-
dividual 2-TM protein (SPCS1) by crystallography is, to our knowl-
edge, unprecedented; the 2-TM proteins alone constitute ~10% of 
the membrane proteome (12). Without the sfGFP coupler, SPCS1 
and JAGN1 only contain small exposed loops, whereas VKOR, 
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Fig. 4. Restraining-based methods for crystal diffraction and phase improvements. (A) Shortening the restrained termini improves the crystal diffraction of 
VKORL. Diffraction patterns are shown for full-length (left) and termini-shortened (right) VKORL restrained by sfGFP. Arrows indicate visible diffraction spots near the 
diffraction limit. (B) Change of crystal packing interactions. The coloring and annotations are the same as in Fig. 3C. (C) Change of relative orientation between the membrane 
protein and sfGFP after termini shortening. The dashed lines indicate disordered termini. (D) Improvement of electron density maps through cross-crystal averaging with 
the coupler protein. The cross-crystal averaging is performed between the sfGFP (2B3P) crystal (averaging mask shown in orange) and the sfGFP-restrained VKORL crystal. 
In addition, the twofold NCS (molecules A and B) is used. (E) Electron density maps of the VKORL region before and after cross-crystal averaging of the low-resolution data. 
Arrows indicate regions with improved electron density. (F) Superimposition of the low-resolution (4.3 Å; blue) and high-resolution models (2.4 Å; red) showing that the 
cross-crystal averaged map allows building of a relatively reliable model at low resolution. (G) Electron density maps of the high-resolution VKORL structure after solvent 
flattening. All the maps are contoured at 1.
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regions, making them difficult targets for traditional membrane 
crystallography. Unlike any other approach, termini restraining now 
affords an effective way to crystallize these proteins.
The underlying principle of termini restraining is fundamentally 
different from conventional protein engineering methods used in 
structural biology. The termini restraining affords a global stabilization 
by inserting the entire membrane protein into a highly stable cou-
pler protein, thereby enhancing the overall stability of the restrained 
constructs. Unlike systematic mutagenesis (2–4), the restraining is a 
rational way of stabilizing overall membrane protein fold (Fig. 1) 
and requires minimal construct screening. An effective mutation 
(2) generally increases the Tm by 1° to 3°C, whereas the restraining 
increases the Tm of DsbB by more than 40°C and the Tm of two 
other proteins by 8° to 9°C. Increased protein thermostability should 
limit the frequency of transiently unfolded states, thereby lower-
ing the probability of protein aggregation in the cellular environ-
ment and in vitro (37). Several restrained proteins show much less 
aggregation during overexpression (Fig. 2G). Consequently, we ob-
tained much higher yield of functional proteins after purification, 
some with increased specific activity (Fig. 2B).
This restraining strategy requires only that the two protein ter-
mini are located at the same side of the membrane, and therefore, it 
is nearly universally useful for proteins with even numbers of TMs 
from any protein family (Table 1). The varying distances between 
the ends of N- and C-terminal TMs of different proteins do not 
affect the ability of termini restraining to stabilize and crystallize 
these proteins (Fig. 5A). Furthermore, termini restraining does not 
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Fig. 5. High-resolution crystal structures of small membrane proteins provide new mechanistic insights into their functions. (A) New membrane protein struc-
tures (resolution in parenthesis) determined by the termini-restraining strategy. The membrane boundary and flexible ends of membrane proteins fused to the sfGFP are 
indicated. The double arrows indicate the distance (C-C atoms) between the ends of N- and C-terminal TMs. (B) Side view of the restrained DsbB Cys104Ser structure 
[same colors as in (A)] superimposed with an independently published crystal structure (PDB code 2ZUQ; blue). PL, periplasmic loop; H, helix. The Fab bound to DsbB in 
2ZUQ is omitted for clarity. (C) Top view of the restrained DsbB structure, superimposed with an NMR structure (2K74; green) that captures a similar electron-transfer state 
(fig. S7). (D) Structural comparison of the catalytic triad in E. coli DsbB and hepatitis A virus 3C protease (1CQQ), a representative cysteine protease (45, 46). (E) Similarity of 
catalytic triads in DsbB and cysteine proteases. Histidine deprotonation of the catalytic cysteine (top) generates the reactive thiolate (bottom). The thiolate in DsbB forms 
a charge-transfer complex with the quinone (UQ), and the thiolate in cysteine protease attacks the scissile bond carbonyl carbon in a peptide substrate.
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essential structural component. As a result, the biological functions 
are retained for the various membrane proteins that we have ana-
lyzed (Fig. 2, A to E). In particular, the example of Mfrn1 suggests 
that the termini restraining is applicable to many classes of trans-
porter proteins by permitting the large rocking motions required 
for their activities. Furthermore, formation of high-order complex, 
such as the cell junction (extracellular side) mediated by Cldn4 
(Fig. 2D), may not be interfered by termini restraining at the other 
side of the membrane (intracellular side). Cautions should be taken, 
however, in that the fused coupler protein may interfere with pro-
tein complex formation or other protein functions at the same side 
of the membrane where the coupler protein is introduced.
The termini restraining affords a combined strategy to obtain 
near-atomic-resolution structures, which are often essential to mech-
anistic understandings of protein function, as with the redox chemistry 
of DsbB that we report here. These well-diffracting crystals only 
form in the presence of the coupler protein, sfGFP, which affords a 
large and versatile polar interface for stable packing interactions 
(Fig. 3, B to D, and fig. S2, B and C) and also increases the relative 
diffraction mass. The restrained constructs are compatible with the 
LCP crystallization method (49) that further improves the structural 
resolution. Linking both termini of the membrane protein to sfGFP 
reduces their relative motions, and optimizing the termini length 
effectively improves crystal diffraction (Fig. 4 and Table 1). The sfGFP 
also enables crystal identification, phase determination, and density 
modification (Figs. 3A and 4D). Together, introducing the sfGFP 
coupler facilitates the entire pipeline of obtaining high-resolution 
crystal structures of small membrane proteins.
Our method is currently limited to small membrane proteins with 
even numbers of TMs but is potentially applicable to those with odd 
numbers of TMs by fusing one component of the associable protein 
entities to an internal loop. The restraining can be extended to use 
other self-associable entities, such as protein domains, protein oligo-
mers, or complexes, or to use intein-mediated polypeptide joining. 
This strategy is not limited to structural studies, as the idea of termini 
restraining may inspire future developments of protein engineering 
and protein design. Moreover, functional membrane proteins with im-
proved stability and increased yield enable their biochemical and bio-
physical studies and fulfil many drug discovery and therapeutic needs.
MATERIALS AND METHODS
Constructs and cloning
Termini restraining was performed by fusing sfGFP residues 1 to 
144 and 146 to end (20) to the N and C termini of target membrane 
proteins (Table 1), respectively. The constructs used for functional 
assays, fluorescence imaging, whole-cell extraction, and crystalliza-
tion have a 10× His tag or FLAG tag added to the C terminus of 
truncated sfGFP (1 to 230). For Tm measurements, the constructs 
are fused into a full-length sfGFP, followed by a PreScission protease 
cleavage site, mCherry, and 10× His tag. The unrestrained constructs 
were generated by tagging the membrane proteins with the PreScission 
site, enhanced GFP (EGFP; or mCherry), and 10× His tag or FLAG 
tag. The unrestrained VKOR and Mfrn1 required the addition of an 
N-terminal small ubiquitin-like modifier protein (SUMO) tag to 
improve their expression level in Pichia pastoris (50). To be consistent, 
the restrained VKOR and Mfrn1 used for the Tm measurements also 
contain the N-SUMO tag. The coding sequences of these constructs 
were cloned into a modified pPICZ-A vector for expression in P. pastoris 
and a pBudCE4.1 vector for expression in HEK293 cells. DsbB 
constructs were cloned into pET28b for FSEC-Tm analysis and crys-
tallization and cloned into pET25b for activity assays. Termini trun-
cations and mutations of the crystallization constructs were performed 
by one-step site-directed mutagenesis (51).
Protein expression
For protein expression in P. pastoris, plasmids were linearized and 
transformed into the Pichia cells by electroporation. Clones with the 
highest expression level were selected by FSEC (38). The cells were 
grown at 30°C for 20 hours in the buffered minimal glycerol (BMG) 
media [1.2% glycerol, 0.34% yeast nitrogen base, 1% ammonium sulfate, 
biotin (0.4 g/ml), and 100 mM potassium phosphate (pH 6.0)]. 
After exchanging to the buffered minimal methanol (BMM) media 
(0.34% yeast nitrogen base, 1% ammonium sulfate, biotin (0.4 g/ml), 
and 200 mM potassium phosphate (pH 6.0)], the cells were induced 
with 0.7% methanol and grown for 1 to 3 days at 25°C. The harvested 
cells were flash-frozen in liquid nitrogen.
The DsbB-containing plasmids were transformed to E. coli C41 cells. 
The cells were grown in LB medium at 37°C to 0.6 optical density (OD). 
Subsequently, the cells were induced with 0.4 mM isopropyl--d- 
thiogalactopyranoside (IPTG) and grown at 25°C overnight. The harvested 
cells were used immediately for protein purification and other assays.
Expression of CD53, Cldn4, and Mfrn1 in HEK293 cells was through 
transient transfection of 0.6 g of plasmids with Lipofectamine 3000. 
The cells were grown in Dulbecco’s modified Eagle’s medium (DMEM) 
with 10% fetal bovine serum at 37°C for 2 days.
Cell imaging
Live Pichia and HEK293 cells were stained with different dyes according 
to the expected subcellular location of different membrane proteins. 
ER-Tracker Blue-White DPX (5 M) was used for the ER membrane, 
FM 4-64 (10 g/ml) was used for the plasma membrane, and 
MitoTracker Red (10 g/ml) was used for the mitochondria. The 
excitation/emission wavelengths were 405/430 nm for ER-Tracker, 
561/575 nm for FM4-64 and MitoTracker, and 488/561 nm for sfGFP 
or EGFP fused to membrane proteins. The live cells were viewed under 
a Zeiss LSM 880 II Airyscan FAST confocal microscope with 63× oil im-
mersion objective for Pichia cells and 40× oil objective for HEK293 cells.
Whole-cell fractionation
Frozen Pichia cells were disrupted with a mixer mill (Retsch) to break 
the cell wall. The cells were resuspended in tris-buffered saline (TBS) 
buffer [0.15 M NaCl and 20 mM tris-HCl (pH 8.0)], and cell mem-
branes were lysed via microfluidization. The same amount of the 
whole-cell suspension was extracted in 2% DDM, 2% SDS, or a mix-
ture of 2% SDS and 6 M urea (adjusted to the same final volume using 
TBS buffer with protease inhibitors) at room temperature for 30 min. 
After ultracentrifugation at 88,760g, the supernatant was heated in the 
SDS sample buffer [with 40 mM dithiothreitol (DTT)] at 90°C for 
10 min and loaded onto SDS–polyacrylamide gel electrophoresis. The 
Western blots used the His tag antibody (GenScript, A00186) for 
most proteins. For human VKOR, anti-VKORC1 antibody (Thermo 
Fisher Scientific, PA560093) was used.
CD53, Cldn4, and Mfrn1 were expressed in HEK293 cells be-
cause the Pichia expression of these proteins results in incorrect 
subcellular locations even for the C-GFP–tagged constructs. The 
cells were resuspended in TBS buffer and extracted in 2% DDM, 
0.1% SDS/1% Triton X-100, or a mixture of 0.1% SDS/1% Triton 
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X-100 and 6 M urea at room temperature for 30 min. After ultra-
centrifugation, the fractionated samples were subjected to Western 
blot using anti-FLAG antibody (Sigma-Aldrich, F2555).
Protein purification
For the purification of most proteins, frozen Pichia cells were broken 
by mixer mill (Retsch) and resuspended in a buffer containing 
150 mM NaCl, 20 mM tris-HCl (pH 8.0), deoxyribonuclease I 
(10 g/ml), and protease inhibitor cocktail. Subsequently, DDM was 
added (2% final concentration) to solubilize the cell membranes for 
3 hours at 4°C. After ultracentrifugation at 130,000g for 20 min, the 
supernatant was incubated with TALON metal affinity resin (Clontech) 
for 3 hours at 4°C. The resin was washed with 10 mM imidazole and 
eluted with 250 mM imidazole in a buffer containing 150 mM NaCl, 
0.2% DDM, and 20 mM tris (pH 8.0). The eluted proteins were con-
centrated and further purified by size exclusion chromatography 
(Superdex 200 or Superose 6) in a buffer containing 150 mM NaCl, 
20 mM tris (pH 8.0), 0.05% DDM, or 0.05% lauryl maltose neopentyl 
glycol (LMNG); DDM was used for Tm measurement and activity 
assay, and LMNG was used for crystallization.
Purification of human VKOR requires the addition of warfarin, 
other vitamin K antagonists, or vitamin K epoxide before the DDM 
solubilization (42). The same ligand concentration was maintained 
during the entire purification process.
The purification of Mfrn1 proteins (50) has the following mod-
ifications (50). The broken cells were resuspended in 150 mM KCl, 
1 mM tris(2-carboxyethyl)phosphine (TCEP), and 50 mM Hepes-
KOH (pH 8.0). For metal affinity chromatography, the washing 
(10 mM imidazole) and elution (250 mM imidazole) buffers contained 
150 mM KCl, 1 mM TCEP, cardiolipin (0.05 mg/ml), 0.2% DDM, 
and 20 mM Mops-KOH (pH 7.5). The buffer used for size exclu-
sion chromatography contained 140 mM KCl, 1 mM TCEP, cardi-
olipin (0.05 mg/ml), 0.2% DDM, and 20 mM Mops-KOH (pH 7.5). 
For functional assays, C-EGFP and N-SUMO tags were removed 
from the proteins by digestion with PreScission protease (20:1, w/w) 
before the size exclusion chromatography.
For the purification of DsbB proteins, E. coli cells were resuspend-
ed in 150 mM NaCl and 20 mM tris (pH 8.0) and then broken by 
sonication. After centrifugation at 4700g for 15 min, the cell mem-
branes were collected by ultracentrifugation at 130,000g for 35 min. 
The membrane fraction was solubilized in a buffer containing 
2% DDM, 150 mM NaCl, and 20 mM tris (pH 8.0) for 2 hours at 
4°C. The membrane debris was removed by ultracentrifugation, and 
the supernatant was incubated with 3 ml of TALON metal affinity 
resin for 2 hours. The resin was washed with 5 mM imidazole and 
eluted with 250 mM imidazole in a buffer containing 0.05% DDM, 
150 mM NaCl, and 20 mM tris (pH 8.0). The proteins were further 
purified through a Superdex 200 column in a buffer containing either 
0.05% DDM, 150 mM NaCl, and 20 mM tris (pH 8.0) for crystalliza-
tion or 0.05% DDM, 50 mM NaCl, and 20 mM Hepes (pH 7.5) for 
the activity assay.
Thermostability FSEC
The peak fractions from size exclusion chromatography were pooled, 
and the protein concentrations of restrained and unrestrained pro-
teins were adjusted to a similar level (usually 1 mg/ml). The re-
strained and unrestrained pairs were simultaneously incubated at 
different temperatures (in a thermocycler) for 10 min. After centrif-
ugation at 20,000g for 1  hour, the supernatant was analyzed by 
FSEC (Shimadzu) using a Superdex 200 or Superose 6 column in a 
buffer containing 0.05% DDM, 150 mM NaCl, and 20 mM tris 
(pH 8.0). The restrained and unrestrained proteins that had been 
heated at the same temperature were loaded to FSEC consecutively 
for precise Tm comparison. Fluorescence of mCherry was moni-
tored with the excitation wavelength at 587 nm and emission at 
610 nm. The peak heights were normalized to that of 4°C samples, 
and the Tm was obtained by fitting the thermostability curves with 
a sigmoidal dose-response equation (52).
Functional assays
The cellular carboxylation assay of VKOR and VKORL activities 
was performed as previously described (53, 54). Briefly, VKORL and 
VKORL clones, along with a luciferase gene, in a pBudCE4.1 vector 
were transfected into a cell line that contains a chimeric factor IX 
Gla and protein C (FIXgla-PC) gene and has endogenous VKORC1 
and VKORL1 genes knocked out. The carboxylation level of secreted 
FIXgla-PC was measured by a sandwich enzyme-linked immuno-
sorbent assay (ELISA) by using the cell culture medium, with luciferase 
activity serving as the control for transfection efficiency. The trans-
fected cells were treated with warfarin at 11 different concentrations 
for inhibition analysis.
In vitro analysis of the epoxide reductase activity of VKOR 
and VKORL used a fluorometric-based assay (31, 40). The same 
concentration of restrained and unrestrained protein was added 
to a buffer containing 20 M vitamin K epoxide, 6 mM DTT, 
0.1% DDM, 0.1 M NaCl, and 20 mM tris (pH 7.6). Fluorescence 
of the reduced product, vitamin K hydroquinone, was detected 
with excitation at 248 nm and emission at 430 nm.
For the E. coli motility assay of DsbB activity, the restrained 
DsbB was transformed to a dsbB HK320 strain (32, 33). Empty 
pET25b vector and pET25b-DsbB-EGFP were used as negative 
and positive controls, respectively. To analyze motility associated 
with each construct, a single colony was grown on a M63 minimal 
plate with 0.3% agar, 0.2% glucose, 0.5 mM IPTG, and ampicillin 
(100 g/ml) at 30°C for 2 days.
The DsbB activity was also assessed through a disulfide-sensitive 
-galactosidase assay. The assay was carried out by transforming 
the constructs into a dsbB E. coli strain with a malF-lacZ fusion 
gene (HK325) (33). The transformants were streaked onto M63 
minimal medium plates [X-galactosidase (100 g/ml), 0.5 mM IPTG, 
1.5% agar, 0.2% glucose, 0.2% maltose, and ampicillin (100 g/ml)] 
and grown at 30°C for 2 days. The maltose/maltodextrin transport sys-
tem permease protein (MALF) fusion to the -galactosidase (malF-lacZ) 
brings part of the protein to the E. coli periplasm and inacti-
vates the enzyme though disulfide bond formation. Thus, the 
-galactosidase is active in the dsbB strain (blue colonies) and 
becomes inactive after the complementation of functional DsbB 
(white colonies).
To analyze the cell junction formed by Cldn4, the restrained 
and unrestrained proteins were transiently expressed in HEK293 
cells. The cells were viewed under a Zeiss Airyscan FAST confocal 
microscope.
To analyze the iron transport activity of restrained and unre-
strained Mfrn1, the purified proteins were reconstituted into 
liposomes. A dried mixture of 1-palmitoyl-2-oleoyl-glycero-3- 
phosphocholine (POPC), 1-palmitoyl-2-oleoyl-sn-glycero-3- 
phosphoethanolamine (POPE), and cardiolipin in a 55:40:5 ratio 
(w/w) was resuspended (with sonication) to 10 mg/ml in 10 mM 
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Mops (pH 7.5), 140 mM KCl, 1 mM sorbitol, and 0.6% sodium 
cholate. The Mfrn1 proteins were added at a 1:50 ratio (w/w) to 
total lipids and incubated at 4°C for 30 min. Subsequently, the mix-
ture was incubated with pretreated Bio-Beads at 4°C overnight. Calcein 
was incorporated into the proteoliposomes by three freeze-thaw cycles, 
and excess calcein was removed by passing the mixture through a 
G50 column. The Fe2+ uptake assay was carried out in 96-well plates 
with calcein fluorescence measured (excitation, 494 nm; emission, 
516 nm) using a plate reader (Molecular Dimensions). After 5 min of 
equilibration, 20 M FeSO4 was added to initiate the Mfrn1-mediated 
transport. After the transport was saturated, 1 M calcimycin was 
added to allow metal influx through this ionophore. The traces of 
calcein fluorescence were plotted as a percentage of maximal quench-
ing after the addition of calcimycin.
The quinone reduction activity of wild-type and mutant DsbB 
constructs was assayed as previously described (55). Briefly, the 200-l 
reaction mixture contained 2 nM DsbB, 20 M reduced DsbA, and 
25 M 2,3-dimethoxy-5-methyl-6-decyl-1,4-benzoquinone (Q0C10) 
in 0.05% DDM, 50 mM NaCl, and 20 mM Hepes (pH 7.5). The 
decrease of absorption at 275 nm due to quinone reduction was re-
corded in a ultraviolet-transparent 96-well plate with a plate reader 
(Molecular Dimensions).
Crystallization and data collection
The restrained proteins were concentrated to approximately 40 mg/ml 
and reconstituted into LCP by thorough mixing with monoolein 
at 2:3 ratio (v/v) using a restrained syringe. With a Gryphon LCP 
robot (Art Robbins), 100-nl drops of the reconstituted protein were 
dispensed onto a glass plate and 800 nl of precipitant solutions was 
overlaid (table S4). The LCP plates were incubated at 22°C. Crystals 
generally appeared overnight and grew to an optimal size after 1 week. 
The crystals were harvested from the mesophase bolus and flash-frozen 
in liquid nitrogen. Diffraction data were collected with a micro-
focus beam and a PILATUS detector at the ID-24 beamlines of Ad-
vanced Photon Source.
Structure determination
MR was conducted with PHASER (56) using the fused sfGFP as the 
search model (PDB code 2B3P) (57). This MR model was rigid body–
refined with REFMAC (58). The partial model phases were im-
proved by solvent flattening and NCS averaging using the programs 
PARROT (59) and DM (60).
For VKORL (the low-resolution data) and DsbB, cross-crystal 
averaging (39) was performed between the existing model and data 
of sfGFP (2B3P) and those of the sfGFP-restrained membrane 
proteins using the program DMMULTI (60). Molecular masks were 
generated and modified using programs NCSMASK and MAPMASK, 
installed in the CCP4 suite (61), and MAPMAN and MAMA, in-
stalled in the UPPSALA software factory (62). Rotation and transla-
tion matrices that match the reference molecule to the target molecule 
were calculated using program PDBSET in the CCP4 suite.
The density-modified maps were used for automatic model 
building by the BUCCANEER software (59). For most datasets, the 
phases after rigid body refinement of the sfGFP model and solvent 
flattening with PARROT with automatically generated mask were 
sufficient for the automatic building of most parts of the membrane 
protein models (Table 1). The models were manually built to com-
pleteness using program COOT (63). The model refinement was by 
programs installed in the PHENIX suites (64).
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/6/51/eabe3717/DC1
View/request a protocol for this paper from Bio-protocol.
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